Title

Safety and IOP-Lowering Effects of WB007
A Phase 1/2a Assessment of WB007 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension
  • Phase

    Phase 1/Phase 2
  • Study Type

    Interventional
  • Status

    Active, not recruiting
  • Study Participants

    77
To evaluate the safety and IOP-lowering effects of WB007 in adults with primary open-angle glaucoma or ocular hypertension in both eyes. This is a 2-part study. Part 1 will look at up to 3 formulations of WB007 ophthalmic solution following a single dose in one eye. Part 2 will look at up to 2 formulations of WB007 (to be selected based on results from Part 1) in both eyes compared with timolol 0.5% for 14 days.
Study Started
Nov 14
2019
Primary Completion
Jan 31
2021
Study Completion
Dec 31
2021
Anticipated
Last Update
Oct 12
2021

Drug Timolol 0.5%

Dosed for 14 days in both eyes

  • Other names: timolol maleate ophthalmic solution 0.5%

Drug Study Treatment 1 WB007

Dosed for 14 days in both eyes

  • Other names: WB007 Formulation 1

Drug Study Treatment 2 WB007

Dosed for 14 days in both eyes

  • Other names: WB007 Formulation 2

Drug Study Treatment 3 WB007

Dosed for 14 days in both eyes

  • Other names: WB007 Formulation 3

Study Treatment 1 Experimental

WB007 Formulation 1

Study Treatment 2 Experimental

WB007 Formulation 2

Study Treatment 3 Experimental

WB007 Formulation 3

Timolol 0.5% Active Comparator

Timolol maleate ophthalmic solution, 0.5%

Criteria

Inclusion Criteria:

Ocular hypertension or primary open-angle glaucoma in each eye

Exclusion Criteria:

History of orthostatic hypotension
Any active ocular disease
Anticipated wearing of contact lenses during study
Contraindication to pupil dilatation
No Results Posted